FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.073A2	APPLICATION NO. 09/811,123
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT ERICKSON et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE March 16, 2001	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
ACH	1	4,450,254	05/22/84	Isley et al.	524	399	06/25/82

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

EXAMINER INITIAL		**OTHER DOCUMENTS** (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
ACH	2 ✓	Arteaga, C.L. et al., "p185$^{c\text{-}erbB\text{-}2}$ Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair," Cancer Research, Vol. 54, pp. 3758-3765 (1994).
ACH	3 ✓	Bacus, S.S. et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells," Cancer Research, Vol. 52, pp. 2580-2589 (1992).
ACH	4 ✓	Fendly, B.M. et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/*neu* Gene Product," Cancer Research, Vol. 50, 1550-1558 (1990).
ACH	5 ✓	Hancock, M.C. et al., "A Monoclonal Antibody against the c-*erbB*-2 Protein Enhances the Cytotoxicity of *cis*-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines," Vol. 51, pp. 4575-4580 (1991).
ACH	6 ✓	Issell, B.F. et al., "Maytansine," Cancer Treatment Reviews, Vol. 5, pp. 199-207 (1978).

EXAMINER	Anne L. Holleran	DATE CONSIDERED	10/21/02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.073A2D	APPLICATION NO. 09/811,123
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT ERICKSON et al.	
(USE SEVERAL SHEETS IF NECESSARY)	FILING DATE March 16, 2001	GROUP 1614

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
AUH	7	Kasprzyk, P.G. et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-*erb*B-2 Monoclonal Antibodies," Cancer Research, Vol. 52, pp. 2771-2776 (1992).
AUH	8	Kern, J.A. et al., "p185^{neu} Expresssion in Human Lung Adenocarcinomas Predicts Shortened Survival," Cancer Research, Vol. 50, pp. 5184-5191 (1990).
AUH	9	Lewis, G.D. et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness," Cancer Research, Vol. 56, pp. 1457-1465 (1996).
AUH	10	Maier, L.A. et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/*neu* Gene Product c-*erb*B-2," Cancer Research, Vol. 51, pp. 5361-5369 (1991).
AUH	11	Park, Joo-Bae et al.," Amplification, Overexpression, and Rearrangement of the *erb*B-2 Protooncogene in Primary Human Stomach Carcinomas," Cancer Research, Vol. 49, pp. 6605-6609 (1989).
AUH	12	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SKREPNIK, NEBOJSA ET AL: "Effects of anti-erbB –2 (HER-2/neu) recombinant oncotoxin Ar209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice" retrieved from STN Database accession no. 126:14452 XP002164007, abstract & CLIN. CANCER RES. (1996), 2(11), 1851-1857.
AUH	13	Sarup, J.C. et al., "Characterization of an Anti-p185^{HER2} Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth," Growth Regulation, Vol. 1, pp. 72-82 (1991).
AUH	14	Shawver, L.K. et al., "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells," Cancer Research, Vol. 54, pp. 1367-1373 (1994).
AUH	15	Skrepnik, N. et al., "Effects of Anti-*erb*B2 (HER-2/*neu*) Recombinant Oncotoxin AR209 on Human Non-Small Cell Lung Carcinoma Grown Orthotopically in Athymic Nude Mice," Clinical Cancer Research, Vol. 2, pp. 1851-1857 (1996).
AUH	16	Vitetta, E.S. et al., "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy," Cancer Research, Vol. 54, pp. 5301-5309 (1994).
AUH	17	Weiner, D.B. et al., "Expression of the *neu* Gene-encoded Protein (P185^{neu}) in Human Non-Small Cell Carcinomas of the Lung," Cancer Research, Vol. 50, pp. 421-425 (1990).
AUH	18	Yokota, J. et al., "Amplification of c-*erb*B2 Oncogene in Human Adenocarcinomas in Vivo," The Lancet, Vol. 1, pp. 765-767 (1986).
AUH	19	Yonemura, Y. et al., "Evaluation of Immunoreactivity for erbB-2 Protein as a Marker of Poor Short Term Prognosis in Gastric Cancer," Cancer Research, Vol. 51, pp. 1034-1038 (1991).

W:\DOCS\ANM\ANM-2033.DOC
082201

EXAMINER	Anne L. Holleran	DATE CONSIDERED	10/21/02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.073A2	APPLICATION NO. 09/811,123
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT ERICKSON et al	
	FILING DATE March 16, 2001	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
AH	1	3,896,111	07/22/75	Kupchan et al.	260	239.3 T	02/20/73
	2	4,137,230	01/30/79	Hashimoto et al.	260	239.3 P	03/15/78
	3	4,151,042	04/24/79	Higashide et al.	195	96	06/29/77
	4	4,248,870	02/03/81	Miyashita et al.	424	248.54	10/18/79
	5	4,256,746	03/17/81	Miyashita et al.	424	248.54	11/09/79
	6	4,260,608	04/07/81	Miyashita et al.	424	248.54	11/09/79
	7	4,265,814	05/05/81	Hashimoto et al.	260	239.3 P	03/19/79
	8	4,294,757	10/13/81	Asai	260	239.3 P	01/15/80
	9	4,307,016	12/22/81	Asai et al.	260	239.3 P	05/27/80
	10	4,308,268	12/29/81	Miyashita et al.	424	248.54	05/28/80
	11	4,308,269	12/29/81	Miyashita et al.	424	248.54	06/06/80
	12	4,309,428	01/05/82	Miyashita et al.	424	248.54	07/23/80
	13	4,313,946	02/02/82	Powell et al.	424	248.54	01/27/81
	14	4,315,929	02/16/82	Freedman et al.	424	248.54	01/27/81
	15	4,317,821	03/02/82	Miyashita et al.	424	248.54	05/22/80
	16	4,322,348	03/30/82	Asai et al.	260	239.3 P	05/14/80
	17	4,331,598	05/25/82	Hasegawa et al.	260	239.3 P	09/17/80
	18	4,361,650	11/30/82	Asai et al.	435	119	08/07/81
	19	4,362,663	12/07/82	Kida et al.	260	239.3 P	09/17/80
	20	4,364,866	12/21/82	Asai et al.	260	239.3 P	09/17/80
	21	4,371,533	02/01/83	Akimoto et al.	424	248.54	09/29/81
	22	4,424,219	01/03/84	Hashimoto et al.	424	248.54	05/03/82
	23	4,968,603	11/06/90	Slamon et al.	435	6	12/31/86
	24	5,183,884	02/02/93	Kraus et al.	536	23.5	12/01/89
	25	5,208,020	05/04/93	Chari et al.	424	85.91	07/13/92
	26	5,416,064	05/16/95	Chari et al.	514	229.5	12/07/92

EXAMINER	DATE CONSIDERED
Anna L. Hellerman	10/21/02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.073A2	APPLICATION NO. 09/811,123
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT ERICKSON et al	
	FILING DATE March 16, 2001	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
AL H	27	5,480,968	01/02/96	Kraus et al.	530	326	11/10/92
	28	5,677,171	10/14/97	Hudziak et al.	435	240.27	08/05/94
	29	5,772,997	06/30/98	Hudziak et al.	424	130.1	05/23/95
	30	5,783,186	07/21/98	Arakawa et al.	424	143.1	12/05/95
	31	5,821,337	10/13/98	Carter et al.	530	387.3	08/21/92
	32	5,824,311	10/20/98	Green et al.	424	138.1	11/30/94
	33	5,837,234	11/17/98	Gentile et al.	424	93.7	06/07/95
	34	5,840,525	11/24/98	Vandlen et al.	435	69.1	05/31/95
	35	5,968,517	10/19/99	Duncan et al.	424	195.1	05/22/97

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	36	✓ 0 425 235 A2	02.05.91	EPO				
	37	✓ WO 89/06692	27.07.89	PCT				
	38	WO 93/21319	28.10.93	PCT				
	39	WO 94/22478	13.10.94	PCT				
	40	✓ WO 94/00136	06.01.94	PCT				
	41	✓ WO 96/16173	30.05.96	PCT				
	42	✓ WO 97/00271	03.01.97	PCT				
	43	WO 97/04801	13.02.97	PCT				
	44	WO 98/02463	22.01.98	PCT				
	45	✓ WO 98/17797	30.04.98	PCT				
	46	✓ WO 99/31140	24.06.99	PCT				
	47	WO 00/20579	13.04.00	PCT				
	48	✓ WO 00/69460	23.11.00	PCT				
	49	✓ WO 01/00238 A1	04.01.01	PCT				
	50	WO 01/00244 A2	04.01.01	PCT				

EXAMINER	DATE CONSIDERED 10/21/02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.073A2	APPLICATION NO. 09/811,123
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT ERICKSON et al	
	FILING DATE March 16, 2001	GROUP 1614

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	51	WO 01/15730 A1	08/03/01	PCT				

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	52	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-*erbB2/neu* and c-*erbB*," Br. J. Cancer, Vol. 57, pp. 358-363 (1988).
	53	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface *HER-2/neu* Antigen," Molecular Carcinogenesis," Vol. 3, pp. 350-362 (1990).
	54	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185^{HER2} Monoclonal Antibody in Patients With HER2/*neu*-Overexpressing Metastatic Breast Cancer," J. Clin. Oncol., Vol. 14, pp. 737-744 (1996).
	55	Borst et al., "Oncogene Alterations in Endometrial Carcinoma," Gynecol. Oncol., Vol. 38, pp. 364-366 (1990).
	56	Carter et al., "Humanization of anti-p185^{HER2} antibody for human cancer therapy," Proc. Natl. Acad. Sci. USA, Vol. 89, pp. 4285-4289 (1992).
	57	Chari et al., "Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs," Cancer Research, Vol. 52, pp. 127-131 (1992).
	58	Cobleigh et al., "Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Cehmotherapy for Metastatic Disease," J. Clin. Oncol., Vol. 17, pp. 2639-2648 (1999).
	59	Cohen et al., "Expression pattern of the *neu* (NGL) gene-encoded growth factor receptor protein (p185^{neu}) in normal and transformed epithelial tissues of the digestive tract," Oncogene, Vol. 4, pp. 81-88 (1989).
	60	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the *neu* oncogene-encoded p185 molecule exert synergistic anti-tumor effects *in vivo*," Oncogene, Vol. 2, pp. 273-277 (1988).
	61	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies," Cell, Vol. 41, pp. 695-706 (1985).
	62	D'Souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene," Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 7202-7206 (1994).
	63	Guérin et al., "Overexpression of Either *c-myc* or *c-erbB-2/neu* Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis," Oncogene Research, Vol. 3, pp. 21-31 (1988).
	64	Gu et al., "Overexpression of *her-2/neu* in human prostate cancer and benign hyperplasia," Cancer Letters, Vol. 99, pp. 185-189 (1996).
	65*	Harweth et al., "Monoclonal Antibodies against the Extracellulr Domain of the erbB-2 Receptor Function as Partial Ligand Agonists," The Journal of Biological Chemistry, Vol. 267, No. 21, pp. 15160-15167 (1992).
	66	Hudziak et al., "p185^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Brest Tumor Cells to Tumor Necrosis Factor," Molecular and Cellular Biology, Vol. 9, No. 3, pp. 1165-1172 (1989).
	67	Klapper et al., "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors," Oncogene, Vol. 14, pp. 2099-2109 (1997).
	68	Kraus et al., "Isolation and characterization of *ERBB3*, a third member of the *ERBB* / epidermal grwoth factor receptor family: Evidence for overexpression in a subset of human mammary tumors," Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 9193-9197 (1989).
	69	Kumar et al., "Regulation of Phosphorylation of the c-*erbB-2/HER2* Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells," Molecular and Cellular Biology, Vol. 11, No. 2, pp. 979-986 (1991).
	70	Lewis et al., "Differential responses of human tumor cell lines to anti-p185^{HER2} monoclonal antibodies," Cancer Immunol. Immunother., Vol. 37, pp. 255-263 (1993).
	71	McCann et al., "c-*erbB-2* Oncoprotein Expression in Primary Human Tumors," Cancer, Vol. 65, pp. 88-92 (1990).
	72*	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human *neu* oncogene product, p185," Oncogene, Vol. 4, pp. 543-548 (1989).
	73	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with *neu* Oncogene Product, p185^{neu}," Methods in enzymology, Vol. 198, pp. 277-290 (1991).

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. GENENT.073A2	APPLICATION NO 09/811,123
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT ERICKSON et al	
	FILING DATE March 16, 2001	GROUP 1614

EXAMINER INITIAL		OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	74	Pietras et al., "Antibody to HER-2/*neu* receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells," Oncogene, Vol. 9, pp. 1829-1838 (1994).
	75	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180*ERBb4*," Letters to Nature, Vol. 366, pp. 473-475 (1993).
	76	Plowman et al., "Ligand-specific activation of HER4/p180 erbB4, a fourth member of the epidermal growth factor receptor family," Proc. Natl. Acad. Sci. USA, Vol. 90, pp. 1746-1750 (1993).
	77	Liu et al., "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids," Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 8618-8623 (1996).
	78	Ross et al., "Prognostic Significance of HER-2/*neu* Gene Amplification Status by Fluorescence In Situ Hybridization of Prostate Carcinoma," Cancer, Vol. 79, pp. 2162-2170 (1997).
	79	Ross et al., "HER-2/*neu* Gene Amplification Status in Prostate Cancer by Fluorescense In Situ Hybridization," Human Pathology, Vol. 28, No. 7, pp. 827-833 (1997).
	80	Sadasivan et al., "Overexpression of HER-2/NEU May be an Indicator of Poor Prognosis in Prostate Cancer," The Journal of Urology, Vol. 150, pp. 126-131 (1993).
	81	Schaefer et al., "γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175," Oncogene, Vol. 15, pp. 1385-1394 (1997).
	82	Scott et al., "p185HER2 Signal Transduction in Breast Cancer Cells," The Journal of Biological Chemistry, Vol. 266, No. 22, pp. 14300-14305 (1991).
	83	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," Journal of clinical Immunology, Vol. 11, No. 3 (1991).
	84	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/*neu* Oncogene," Science, Vol. 235, pp. 177-182 (1987).
	85	Slamon et al., "Studies of the HER-2/*neu* Proto-oncogene in Human Breast and Ovarian Cancer," Science, Vol. 244, pp. 707-712 (1989).
	86	Sliwkowski et al., "Coexpression of *erbB2* and *erbB3* Proteins Reconstitutes a High Affinity Receptor for Heregulin," The Journal of Biological Chemistry, Vol. 269, No. 20, pp. 14661-14665 (1994).
	87	Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonl antibodies to the ERBB2 receptor on tumor growth," Proc. Natl. Acad. Sci. USA, Vol. 88, pp. 8691-8695 (1991).
	88	Tagliabue et al., "Selection of Monoclonal Antibodies Which Induce Internalization and Phosphorylation of p185HER2 and Growth Inhibition of Cells with HER2/*NEU* Gene Amplification," Int. J. Cancer, Vol. 47, pp. 933-937 (1991).
	89	Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas, " Pathobiology, Vol. 59, pp. 46-52 (1991).
	90	Xu et al., "Antibody-Induced Growth Inhibition is Mediated Through Immunochemically and Functionally Distinct Epitopes on the Extracellular Domain o *c-erbB*-2 (HER-2/*neu*) Gene Product," Vol. 53, pp. 401-408 (1993).
	91	Zhau et al., "Amplification and Expression of the *c-erb* B-2/*neu* Proto-Oncogene in Human Bladder Cancer," Molecular Carcinogenesis, Vol. 3, pp. 254-(1990).
	92	King et al., "Amplification of a Novel *v-erbB*-Related Gene in a Human Mammary Carcinoma," Science, Vol. 229, pp. 974-976 (1985).
	93	Fukushige et al., "Localization of a Novel *v-erbB*-Related Gene, *c-erbB*-2, on Human Chromosome 17 and Its Amplification in a Gastric Cancer Cell L Molecular and Cellular Biology, Vol. 6, No. 3, pp. 955-958 (1986).
	94	DATABASE CHEMABS Onlinel, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BRECHBIEL, MARTIN W. ET AL: "Synthesis and evaluation of antiproliferative activity of a geldanamycin-herceptin immunoconjugate." Retrieved from STN Database accession no. 2000:796068, XP002164006, abstract & ABSTR. PAP. – AM. CHEM. SOC. (2000), 220TH, MEDI-071.

W:\DOCS\GRD\GRD-5817.DOC
062201

EXAMINER	DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATIOI IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.